Response to Vilariño-Güell et al. In response to our paper, 1 Vilariño-Güell et al. 2 genotyped FKBP6 p.R183C in 2383 multiple sclerosis (MS) patients (1952 with familial MS and 431 with sporadic MS) and 1055 controls from the Canadian population. They found a minor allele frequency (MAF) of 0.31% in all MS patients and MAF of 0.28% in controls, but the difference was not significant. They also showed that MAF of this variant was 1.4 times higher (we found 2× higher) in familial MS compared to sporadic MS (MAF 0.33% vs 0.23%, respectively), although not statistically significant. FKBP6 p.R183C did not segregate in their Canadian families.
It is important to emphasize that rare alleles have different genetic structures in ethnically different populations. 3 The frequency of this variant was in fact 3× higher in the Dutch control population (0.95%) compared to Canadian controls (0.28%) and the Exome Aggregation database (0.32%). In this light, one should be cautious with one-by-one comparison of the populations, even seemingly comparable ones.
Furthermore, rare variants can be private to a specific family of a specific origin. The lack of segregation in Canadian families does not simply eliminate the possibility that FKBP6 p.R183C is a potentially disease causing variant for this specific Dutch MS family. As MS is a heterogenous disorder with a high degree of variability between individuals and ethnicities in terms of clinical features, genetics, pathology, and immunological phenotypes, 4 it is possible that other factors or a combination of factors have the upper hand in the Canadian families in terms of MS susceptibility. The lack of association of this variant with MS in Canadian case-control analysis may be due to the lack of power resulting from the rarity of the variant in this population.
The linkage area on chromosome 7 (chr7:69877261-73139762) contains about ~40 genes. We revisited raw exome sequencing data and inspected the alignments in this area using integrative genomics viewer (IGV). 5 No inter-chromosomal rearrangements were observed in four sequenced individuals. As stated in Mescheriakova et al., 1 frameshift insertions, deletions, splicesite mutations, stopgain, and stoploss variants located in the linkage region shared by sequenced individuals were inspected, but no potential candidates have been identified. The authors further comment on the possibility that the true pathogenic variant could have been overlooked because of variable degree of coverage. A sufficient coverage on a single base resolution of at least 20× is usually necessary for reliable detection of sequence variations. 6 At least 10× of coverage was achieved for 90.1% and 20× for 71% of the whole exome for four samples. Similar coverage was found for chromosome 7, including the linkage area. It is a general fact that not all targeted regions are captured at the same efficiency in whole exome sequencing (WES). Even not every kit covers the same exome regions. 7 The possibility of missing out the 'actual disease causing variant' thus cannot be ruled out here. However, even with deep coverage, models for single nucleotide polymorphisms (SNP) calling can sometime lead to considerable false positive rates 8 ; thus not only the measure of coverage but other stringent filtering parameters are also important. Our sequencing data went through a well-designed quality control pipeline to ensure the quality of the called variants.
In our paper, we made an effort to identify a risk variant by means of WES which was located in the linkage area and segregated with MS in the Dutch family. Our data analysis met the criteria needed for reliable detection. Despite this, it is possible that FKBP6 p.R183C may not be the actual causal variant but rather be in linkage disequilibrium (LD) with another risk variant not covered by exome sequencing, as WES might miss out on variants in inadequately targeted regions and is unsuitable for finding potential candidates in cryptic exons or non-coding regions.
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